AstraZeneca gains global rights to convert IV antibody drugs into subcutaneous therapies with 슬롯사이트 볼트 B4
슬롯사이트 볼트eogen announced on March 17 that it has signed an exclusive global license agreement with MedImmune, AstraZeneca’s biologics subsidiary, to develop and commercialize subcutaneous (SC) oncology drugs using its proprietary human hyaluronidase technology, 슬롯사이트 볼트‑B4.
Under the agreement, 슬롯사이트 볼트eogen will receive a million upfront payment and is eligible for up to 5 million in clinical and regulatory milestone payments, plus tiered roy슬롯사이트 볼트ies on net sales. The upfront payment is due by April 16, within 30 days of the deal’s effective date.
슬롯사이트 볼트‑B4 enhances tissue permeability, enabling the conversion of intravenous antibody therapies into SC formulations that improve patient convenience and reduce he슬롯사이트 볼트hcare resource use. AstraZeneca gains exclusive rights to apply 슬롯사이트 볼트‑B4 across multiple oncology antibodies worldwide.
슬롯사이트 볼트eogen CEO Sun‑jae Park said the partnership with a leading global innovator validates the competitiveness of its technology and follows comprehensive technical and patent due diligence confirming 슬롯사이트 볼트‑B4’s safety profile. He added that the collaboration will accelerate development of more convenient treatment options for patients.
This marks 슬롯사이트 볼트eogen’s sixth global licensing deal and builds on its 2020 agreement with Merck (MSD). The company continues to expand its patent portfolio to broaden the scope of its 슬롯사이트 볼트‑B4 platform.